Avalon Advisors LLC Boosts Position in Shire PLC (SHPG)
Avalon Advisors LLC increased its position in shares of Shire PLC (NASDAQ:SHPG) by 32.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,874 shares of the biopharmaceutical company’s stock after buying an additional 2,657 shares during the quarter. Avalon Advisors LLC’s holdings in Shire were worth $1,893,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Third Point LLC bought a new position in shares of Shire during the third quarter worth about $290,032,000. Gateway Investment Advisers LLC grew its stake in Shire by 1.8% in the fourth quarter. Gateway Investment Advisers LLC now owns 57,573 shares of the biopharmaceutical company’s stock valued at $10,020,000 after purchasing an additional 1,028 shares in the last quarter. Credit Suisse AG grew its stake in Shire by 67.2% in the third quarter. Credit Suisse AG now owns 396,626 shares of the biopharmaceutical company’s stock valued at $71,896,000 after purchasing an additional 159,395 shares in the last quarter. Checchi Capital Advisers LLC bought a new position in Shire in the fourth quarter valued at approximately $208,000. Finally, Abrams Capital Management L.P. bought a new position in Shire in the third quarter valued at approximately $407,338,000. Institutional investors and hedge funds own 20.23% of the company’s stock.
A number of research analysts have weighed in on SHPG shares. BidaskClub upgraded Shire from a “hold” rating to a “buy” rating in a research note on Tuesday, December 25th. SunTrust Banks downgraded Shire from a “buy” rating to a “hold” rating in a research note on Tuesday, December 11th. Cantor Fitzgerald set a $222.00 price target on Shire and gave the company a “buy” rating in a research note on Thursday, December 20th. ValuEngine upgraded Shire from a “sell” rating to a “hold” rating in a research note on Thursday, December 6th. Finally, William Blair downgraded Shire from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 20th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Shire has an average rating of “Buy” and a consensus target price of $201.60.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Further Reading: Do back-end load funds outperform no-load funds?
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.